The Road Ahead: Long-Term Monitoring & Complications

As the initial “flare” of disabling pansclerotic morphea of childhood (DPMC) is brought under control with medication, the focus of care shifts to long-term monitoring and managing the physical aftermath. Because DPMC can affect every layer of tissue down to the bone, its impact can continue to evolve even after the active inflammation has stopped ^[1][2].

Long-Term Musculoskeletal Complications

The depth of DPMC makes it one of the most physically challenging forms of scleroderma. Because the hardening (sclerosis) can wrap around limbs and dive deep into the fascia and muscle, it can cause:

• Contractures: Severe, painful contractures (tendon or soft-tissue shortening that impairs joint motion) are common, and in some cases can lead to ankylosis or growth-related bony changes ^[1][3]. A spectrum of functional impairment exists, and complete loss of mobility is not inevitable.
• Limb-Length Discrepancy: If the disease affects the growth plates in a child’s bones, one limb may grow more slowly than the other, leading to a significant difference in length ^[4][5].
• Deep Atrophy: The loss of muscle and subcutaneous fat can leave limbs looking thin or “wasted,” which further limits strength and function ^[1][2].

The Risk of Squamous Cell Carcinoma (SCC)

There is a rare but important risk of developing squamous cell carcinoma (a type of skin cancer) within chronic, non-healing ulcers, supported mainly by reports in chronic wounds ^[6][7]. Infection and trauma are more common causes of wound changes.

• The Warning Signs: You must alert your medical team if a long-standing ulcer starts to enlarge, becomes unusually painful, bleeds easily, develops foul-smelling drainage, or grows “heaped-up” tissue at the edges ^[7].
• Prompt Assessment: While metastasis (spreading) of SCC arising in chronic ulcers is uncommon, any suspicious change in an ulcer warrants prompt dermatologic assessment and possible biopsy ^[7].

Monitoring Disease Activity vs. Damage

Your child’s team will use specific tools to distinguish between “active” inflammation (which needs more medication) and “permanent” damage (which needs therapy or surgery).

• LoSCAT: The Localized Scleroderma Cutaneous Assessment Tool is a useful validated clinician tool for tracking your child’s progress ^[8]. It provides two separate scores:
  • mLoSSI: Tracks active inflammation (redness, skin thickness) ^[8].
  • LoSDI: Tracks permanent damage (skin thinning, color changes) ^[9]. However, LoSCAT is not a complete measure of deep fascial, functional, or bone issues.
• Imaging: MRI can help assess if the disease is still active deep in the fascia or muscle, even if the skin looks quiet on the surface, but its frequency is individualized ^[10][11]. Thermography (heat-sensing imaging) may also be used to look for “hot spots” of inflammation, though it is often used as a supplement to the physical exam ^[8][12].

Relapse and Surveillance

The risk of the disease returning (relapse) is highest in the first two years after systemic treatment (like methotrexate) is stopped ^[2][13].

• High-Risk Period: In broader juvenile localized scleroderma cohorts, studies show that about 22% of children may experience a relapse, typically occurring around 20 months after stopping medication ^[2]. DPMC-specific estimates are uncertain.
• Follow-Up Schedule: During these first two years, frequent clinic visits on an individualized schedule are important to catch any “new” hardening early ^[2][14].

When Surgery is an Option

Elective reconstructive surgeries are generally deferred until the disease is documented to be inactive (often for 1-2 years), though timing depends on function, pain, ulcers, and remaining growth ^[6]. Urgent surgery for infection or necrosis occurs as needed.

• Contracture Release: Orthopedic surgery may be needed to physically “release” tightened tendons or joints to improve movement ^[4].
• Reconstructive Options: In cases of severe tissue loss, specialists may use autologous fat transfer (moving fat from one part of the body to another) or microsurgical flap reconstruction to improve the appearance and padding of the affected area ^[15][6].
• Limb Balancing: If a significant limb-length discrepancy develops, surgeries to slow the growth of the “longer” leg (epiphysiodesis) may be discussed to help balance the child’s gait ^[4]. This requires careful prediction of final limb-length discrepancy and sufficient remaining growth.